Tuning Cytokine Receptor Signaling by Reorienting Dimer Geometry with Surrogate Ligands Graphical

[1]  M. Waters,et al.  In vivo targeting of the growth hormone receptor (GHR) Box1 sequence demonstrates that the GHR does not signal exclusively through JAK2. , 2010, Molecular endocrinology.

[2]  Robert M Stroud,et al.  Mechanistic Diversity of Cytokine Receptor Signaling Across Cell Membranes , 2004, Science's STKE.

[3]  R. Lerner,et al.  Selecting agonists from single cells infected with combinatorial antibody libraries. , 2013, Chemistry & biology.

[4]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[5]  Pavel Kovarik,et al.  Serine phosphorylation of STATs , 2000, Oncogene.

[6]  Ayalew Tefferi,et al.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.

[7]  P. Heinrich,et al.  Studies on the Interleukin-6-type Cytokine Signal Transducer gp130 Reveal a Novel Mechanism of Receptor Activation by Monoclonal Antibodies* , 2000, The Journal of Biological Chemistry.

[8]  D. Shaw,et al.  How IGF-1 activates its receptor , 2014, eLife.

[9]  Jingsheng Liu,et al.  The activation and differential signalling of the growth hormone receptor induced by pGH or anti-idiotypic monoclonal antibodies in primary rat hepatocytes , 2013, Molecular and Cellular Endocrinology.

[10]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[11]  S. Imbeaud,et al.  Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours , 2009, Nature.

[12]  S. Constantinescu,et al.  Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. , 2003, Molecular cell.

[13]  W. Vainchenker,et al.  A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. , 2005, Trends in molecular medicine.

[14]  J. Violin,et al.  beta-arrestin-biased agonism at the beta2-adrenergic receptor. , 2008, The Journal of biological chemistry.

[15]  M. Kawahara,et al.  The influence of domain structures on the signal transduction of chimeric receptors derived from the erythropoietin receptor. , 2009, Journal of biochemistry.

[16]  A. Sergé,et al.  Dynamic multiple-target tracing to probe spatiotemporal cartography of cell membranes , 2008, Nature Methods.

[17]  Jian-xin Lin,et al.  IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. , 2011, Current opinion in immunology.

[18]  Hans-Peter Kriegel,et al.  Density-Based Clustering in Spatial Databases: The Algorithm GDBSCAN and Its Applications , 1998, Data Mining and Knowledge Discovery.

[19]  K. Garcia,et al.  Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. , 2005, Science.

[20]  R. Levine,et al.  X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. , 2005, Blood.

[21]  J. Tavernier,et al.  Dimerization of the Interferon Type I Receptor IFNaR2–2 Is Sufficient for Induction of Interferon Effector Genes but Not for Full Antiviral Activity* , 1999, The Journal of Biological Chemistry.

[22]  O. Silvennoinen,et al.  Signaling through the hematopoietic cytokine receptors. , 1995, Annual review of immunology.

[23]  I. Behrmann,et al.  JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms , 2013, JAK-STAT.

[24]  C. Pecquet,et al.  Orientation‐specific signalling by thrombopoietin receptor dimers , 2011, The EMBO journal.

[25]  A. Plückthun,et al.  Bispecific Designed Ankyrin Repeat Proteins (DARPins) Targeting Epidermal Growth Factor Receptor Inhibit A431 Cell Proliferation and Receptor Recycling* , 2011, The Journal of Biological Chemistry.

[26]  H. Blau,et al.  Structural and Mechanistic Insights into Nerve Growth Factor Interactions with the TrkA and p75 Receptors , 2007, Neuron.

[27]  D. Riese.  Ligand-based receptor tyrosine kinase partial agonists: new paradigm for cancer drug discovery? , 2011, Expert opinion on drug discovery.

[28]  J. Wells,et al.  Structure and function of human growth hormone: implications for the hematopoietins. , 1993, Annual review of biophysics and biomolecular structure.

[29]  M. Ballinger,et al.  Will any dimer do? , 1998, Nature Structural Biology.

[30]  Debashis Sahoo,et al.  Gene Expression Commons: An Open Platform for Absolute Gene Expression Profiling , 2012, PloS one.

[31]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .

[32]  M. Ultsch,et al.  Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. , 1992, Science.

[33]  M. Dottore,et al.  The Structure of the GM-CSF Receptor Complex Reveals a Distinct Mode of Cytokine Receptor Activation , 2008, Cell.

[34]  G. Bu,et al.  Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[35]  A. Lim,et al.  A diversity of antibody epitopes can induce signaling through the erythropoietin receptor. , 2010, Biochemistry.

[36]  J. Piehler,et al.  Rapid transfer of transmembrane proteins for single molecule dimerization assays in polymer-supported membranes. , 2014, ACS chemical biology.

[37]  K. Christopher Garcia,et al.  Molecular and Structural Basis of Cytokine Receptor Pleiotropy in the Interleukin-4/13 System , 2008, Cell.

[38]  R. Lerner,et al.  Selection of antibodies that regulate phenotype from intracellular combinatorial antibody libraries , 2012, Proceedings of the National Academy of Sciences.

[39]  H. Tsunoda,et al.  Effective screening method of agonistic diabodies based on autocrine growth. , 2009, Journal of immunological methods.

[40]  D E Koshland,et al.  A piston model for transmembrane signaling of the aspartate receptor. , 1999, Science.

[41]  Guillermo A. Gomez,et al.  Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor , 2014, Science.

[42]  H. Hieronymus,et al.  FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR , 2011, Nature.

[43]  Airlie J. McCoy,et al.  Solving structures of protein complexes by molecular replacement with Phaser , 2006, Acta crystallographica. Section D, Biological crystallography.

[44]  R. Williams,et al.  Crystal structure of a diabody, a bivalent antibody fragment. , 1994, Structure.

[45]  Jamie B. Spangler,et al.  Insights into cytokine-receptor interactions from cytokine engineering. , 2015, Annual review of immunology.

[46]  J. Bazan,et al.  Haemopoietic receptors and helical cytokines. , 1990, Immunology today.

[47]  M. Dahan,et al.  Self-controlled monofunctionalization of quantum dots for multiplexed protein tracking in live cells. , 2010, Angewandte Chemie.

[48]  H. Lodish,et al.  The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. , 2001, Molecular cell.

[49]  K. Garcia,et al.  Structural snapshots of full-length Jak1, a transmembrane gp130/IL-6/IL-6Rα cytokine receptor complex, and the receptor-Jak1 holocomplex. , 2011, Structure.

[50]  I. Wilson,et al.  Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. , 1999, Science.

[51]  W. Vainchenker,et al.  Differential signalling of NH2-terminal flag-labelled thrombopoietin receptor activated by TPO or anti-FLAG antibodies. , 2004, Cellular signalling.

[52]  Wen He,et al.  An antagonist peptide–EPO receptor complex suggests that receptor dimerization is not sufficient for activation , 1998, Nature Structural Biology.

[53]  W. Windsor,et al.  Crystal structure of a complex between interferon-gamma and its soluble high-affinity receptor. , 1995, Nature.

[54]  A. Plückthun,et al.  Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. , 2013, Structure.

[55]  M. Cristina Cardoso,et al.  A Versatile Nanotrap for Biochemical and Functional Studies with Fluorescent Fusion Proteins*S , 2008, Molecular & Cellular Proteomics.

[56]  P. Gregersen,et al.  Structural biology of shared cytokine receptors. , 2009, Annual review of immunology.

[57]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[58]  N. Hynes,et al.  Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. , 1992, The Journal of biological chemistry.

[59]  K. Garcia,et al.  Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. , 2003, Science.

[60]  M. Waters,et al.  An agonist-induced conformational change in the growth hormone receptor determines the choice of signalling pathway , 2008, Nature Cell Biology.

[61]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[62]  H. Miyazaki,et al.  Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor , 2008, Nature Biotechnology.

[63]  M. Babu,et al.  Molecular signatures of G-protein-coupled receptors , 2013, Nature.

[64]  A. Ferrando,et al.  Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia , 2011, Nature Genetics.

[65]  V. Pande,et al.  Mechanistic and structural insight into the functional dichotomy between interleukin-2 and interleukin-15 , 2012, Nature Immunology.

[66]  Peter O. Krutzik,et al.  Structural Linkage between Ligand Discrimination and Receptor Activation by Type I Interferons , 2011, Cell.

[67]  Robert M. Stroud,et al.  Efficiency of signalling through cytokine receptors depends critically on receptor orientation , 1998, Nature.

[68]  W. Vainchenker,et al.  The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. , 2007, Blood.

[69]  A. Yoshimura,et al.  Ligand-induced activation of chimeric receptors between the erythropoietin receptor and receptor tyrosine kinases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[70]  Sandra A. Moore,et al.  MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.

[71]  Stefan N. Constantinescu,et al.  The Erythropoietin Receptor: Structure, Activation and Intracellular Signal Transduction , 1999, Trends in Endocrinology & Metabolism.

[72]  Enrico A. Stura,et al.  Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8 Å , 1996, Science.

[73]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[74]  H. Lodish,et al.  The prolactin receptor rescues EpoR-/- erythroid progenitors and replaces EpoR in a synergistic interaction with c-kit. , 1998, Blood.

[75]  Peter O. Krutzik,et al.  Intracellular phospho‐protein staining techniques for flow cytometry: Monitoring single cell signaling events , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[76]  H. Lodish,et al.  Dimerization by a Cytokine Receptor Is Necessary for Constitutive Activation of JAK2V617F* , 2008, Journal of Biological Chemistry.

[77]  S. Schreiber,et al.  Dimerization as a regulatory mechanism in signal transduction. , 1998, Annual review of immunology.